Vasoactive Intestinal Polypeptide (PHM27/VIP)-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Vasoactive Intestinal Polypeptide (PHM27/VIP), , a peptide hormone consisting of 28 amino acids that promotes contractility, vasodilation, glycogenosis, arterial blood pressure and others, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 11/May/2019, 6.55 am

Natural product-based pain therapy: Danhong injection increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 11/May/2019, 6.37 am
May 11, 2019
Have copious amounts of natural sugar Rhamnose to stay protected against myocardial diseases: L- Rhamnose protects against and promotes functional recovery after Myocardial Infarction:  L- Rhamnose (6-deoxy-L-Mannose) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 12/May/2019, 6.31 pm
May 12, 2019
Show all

Introduction: What they say

A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April  2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20.761)by Prof Tzahor E, D’Uva E, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Vasoactive Intestinal Polypeptide (PHM27/VIP)-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Vasoactive Intestinal Polypeptide (PHM27/VIP), a peptide hormone consisting of 28 amino acids that promotes contractility, vasodilation, glycogenosis, arterial blood pressure and others, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene


From the significance of the study to Public health relevance: 

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs and (iv) a side-effect-free Natural product-based drug.

 


From research findings to Therapeutic opportunity: 

This study suggests, for the first time, how Vasoactive Intestinal Polypeptide (PHM27/VIP) may protect against cardiovascular diseases. PHM27/VIP, by increasing the expression of its target gene, it may: (1) increase ERBB2/Her2 expression; (2) induce cardiomyocyte (CM) dedifferentiation and proliferation; and (3) cardiomyocyte (CM) redifferentiation and regeneration.  Thus, pharmacological formulations encompassing “Vasoactive Intestinal Polypeptide  inducers, either alone or in combination with other drugs,” may be used to promote cardiac dedifferentiation and regeneration.

Figure1. Mechanistic insights into how Vasoactive Intestinal Polypeptide (PHM27/VIP) may promote cardiac dedifferentiation and regeneration. PHM27/VIP, by increasing the expression of its target genes, it may upregulate the expression of ERRB2/HER2 and promote cardiac dedifferentiation and regeneration

Figure 2. Vasoactive Intestinal Polypeptide (PHM27/VIP) may promote cardiac regeneration through induction of Her2/Erbb2

Given the mechanistic basis of how Vasoactive Intestinal Polypeptide (PHM27/VIP)  may aid in cardiomyocyte survival and regeneration,  medical practitioners and cardiologists may consider treating myocardial patients with pharmacological compounds that induce the expression of Vasoactive Intestinal Polypeptide (PHM27/VIP) or itself, as they may aid in cardiomyocyte regeneration following myocardial infarction

[easy_payment currency=”USD”]


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:  Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $ 500#

Undisclosed (mechanistic insights) information: How does Vasoactive Intestinal Polypeptide (PHM27/VIP)  increase the expression of  ERBB2/Her2?

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L.,   Vasoactive Intestinal Polypeptide (PHM27/VIP)-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Vasoactive Intestinal Polypeptide (PHM27/VIP), , a peptide hormone consisting of 28 amino acids that promotes contractility, vasodilation, glycogenosis, arterial blood pressure and others, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 11/May/2019, 6.55 am,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.